Synergistic targeting of CHK1 and mTOR in MYC-driven tumors

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• MYC oncogene deregulation is common in human cancers, correlating with poor prognosis and treatment resistance.
• Directly targeting MYC has proven challenging, making indirect inhibition strategies a focus for cancer therapy.
• Checkpoint kinase 1 (CHK1) regulates cell cycle checkpoints and protects cancer cells from replicative stress.

Purpose of the Study:

• To investigate the role of MYC in regulating CHK1 transcription.
• To evaluate the efficacy of combined CHK1 and mTOR inhibition in MYC-driven cancers.
• To elucidate the underlying mechanisms of this combined therapeutic approach.

Main Methods:

• Utilized c-MYC-driven T-acute lymphoblastic leukemia and N-MYC-driven neuroblastoma models.
• Assessed the direct binding of MYC proteins to the CHK1 locus and their transcriptional activation.
• Administered CHIR-124 (CHK1 inhibitor) and rapamycin (mTOR inhibitor) as single agents and in combination.
• Analyzed the impact on cell viability, replicative stress, and tumor progression in vitro and in vivo.

Main Results:

• Both c-MYC and N-MYC were found to directly bind to and activate CHK1 transcription.
• Combination therapy with CHIR-124 and rapamycin demonstrated synergistic lethality in MYC-overexpressing cancer cells.
• Rapamycin's inactivation of CAD enzyme exacerbated CHIR-124-induced replicative stress.
• Dual treatment significantly impeded tumor progression in vivo models of T-acute lymphoblastic leukemia and neuroblastoma.

Conclusions:

• Simultaneous targeting of CHK1 and mTOR represents a potent co-treatment strategy for MYC-mediated tumors.
• This combination therapy offers a novel therapeutic avenue for challenging hematologic and solid cancers.
• Understanding the interplay between MYC, CHK1, mTOR, and pyrimidine synthesis is crucial for developing effective cancer treatments.